AANP is part of a coalition of health professionals asking Congress to examine the FDA’s implementation of the Drug Quality and Security Act – specifically, the agency’s unwavering stance that the law does not allow traditional compounding pharmacies to provide medications for office use.
The coalition recently delivered a letter to congressional leaders, noting that compounded drugs are essential for many patients, especially when an FDA-approved drug is neither available nor appropriate to treat their condition. The letter pointed to congressional intent that the states continue to have authority over office use, and that patient-specific prescriptions should not be required.
The coalition stressed that, ultimately, the FDA’s position “interferes with the practice of medicine and decreases patient access to medications.” AANP and its partners, e.g., the International Association of Compounding Pharmacists, will be pressing Congress to hold hearings on the implementation of the law and requesting meetings with the FDA on the issue of office use.
If you are finding that certain compounded drugs are becoming scarce or costing a great deal more, let AANP know about it. Fill out this quick survey
. The more information we collect, the stronger a case can be made that patients are being harmed.